1 The endogenous cannabinoid, anandamide, has been reported to induce an`endothelium-derived hyperpolarizing factor (EDHF)-like' relaxation in vitro. We therefore investigated the e ects of cannabinoid CB1 receptor agonists; HU 210, D 9 -tetrahydrocannabinol (D 9 -THC) and anandamide, and a CB1 antagonist/inverse agonist, SR 141716A, on nitric oxide (NO) and EDHF-mediated relaxation in precontracted rings of porcine coronary, rabbit carotid and mesenteric arteries. 2 In rings of mesenteric artery HU 210 and D 9 -THC induced endothelium-and cyclo-oxygenaseindependent relaxations which were sensitive to SR 141716A. Anandamide (0.03 ± 30 mM) induced a slowly developing, endothelium-independent relaxation which was abolished by diclofenac and was therefore mediated by cyclo-oxygenase product(s). None of the CB1 agonists tested a ected the tone of precontracted rings of rabbit carotid or porcine coronary artery. 3 In endothelium-intact segments, HU 210, D 9 -THC and anandamide did not a ect NO-mediated responses but under conditions of continuous NO synthase/cyclo-oxygenase blockade, signi®cantly inhibited acetylcholine and bradykinin-induced relaxations which are attributed to the production of EDHF. The e ects of HU 210 and D 9 -THC were not observed when experiments were performed in the presence of SR 141716A suggesting the involvement of the CB1 receptor. 4 In a patch clamp bioassay of EDHF production, HU 210 decreased the EDHF-mediated hyperpolarization of detector smooth muscle cells when applied to the donor segment but was without e ect on the membrane potential of detector cells. The inhibition of EDHF production was unrelated to alterations in Ca 2+ -signalling or cytochrome P450 activity. 5 These results suggest that the activation of endothelial CB1 receptors appears to be negatively coupled to the production of EDHF.